Tweet
Eur J Pharm Biopharm. 2015 Apr 17. pii: S0939-6411(15)00170-8. doi: 10.1016/j.ejpb.2015.04.004. [Epub ahead of print]
Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.
Patil HP1, Murugappan S2, de Vries-Idema J1, Meijerhof T1, de Haan A1, Frijlink HW2, Wilschut J1, Hinrichs WL2, Huckriede A3.
Author information
Abstract
Stable vaccines administered to the lungs by inhalation could circumvent many of the problems associated with current immunizations against respiratory infections. We earlier provided proof of concept in mice that pulmonary delivered whole inactivated virus (WIV) influenza vaccine formulated as a stable dry powder effectively elicits influenza-specific antibodies in lung and serum. Yet, mucosal IgA, considered particularly important for protection at the site of virus entry, was poorly induced. Here we investigate the suitability of various Toll-like receptor (TLR) ligands and the saponin-derived compound GPI-0100 to serve as adjuvant for influenza vaccine administered to the lungs as dry powder. The TLR ligands palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4), monophosphoryl lipid A (MPLA) and CpG oligodeoxynucleotides (CpG ODN) as well as GPI-0100 tolerated the process of spray freeze-drying well. While Pam3CSK4 had no effect on systemic antibody titers, all the other adjuvants significantly increased influenza-specific serum and lung IgG titers. Yet, only GPI-0100 also enhanced mucosal IgA titers. Moreover, only GPI-0100-adjuvanted WIV provided partial protection against heterologous virus challenge. Pulmonary immunization with GPI-0100-adjuvanted vaccine did not induce an overt inflammatory response since influx of neutrophils and production of inflammatory cytokines were moderate and transient and lung histology was normal. Our results indicate that a GPI-0100-adjuvanted dry powder influenza vaccine is a safe and effective alternative to current parenteral vaccines.
Copyright ? 2015. Published by Elsevier B.V.
KEYWORDS:
Adjuvants; Pulmonary vaccination; Spray freeze-drying; Whole inactivated virus
PMID: 25896446 [PubMed - as supplied by publisher]
Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.
Patil HP1, Murugappan S2, de Vries-Idema J1, Meijerhof T1, de Haan A1, Frijlink HW2, Wilschut J1, Hinrichs WL2, Huckriede A3.
Author information
Abstract
Stable vaccines administered to the lungs by inhalation could circumvent many of the problems associated with current immunizations against respiratory infections. We earlier provided proof of concept in mice that pulmonary delivered whole inactivated virus (WIV) influenza vaccine formulated as a stable dry powder effectively elicits influenza-specific antibodies in lung and serum. Yet, mucosal IgA, considered particularly important for protection at the site of virus entry, was poorly induced. Here we investigate the suitability of various Toll-like receptor (TLR) ligands and the saponin-derived compound GPI-0100 to serve as adjuvant for influenza vaccine administered to the lungs as dry powder. The TLR ligands palmitoyl-3-cysteine-serine-lysine-4 (Pam3CSK4), monophosphoryl lipid A (MPLA) and CpG oligodeoxynucleotides (CpG ODN) as well as GPI-0100 tolerated the process of spray freeze-drying well. While Pam3CSK4 had no effect on systemic antibody titers, all the other adjuvants significantly increased influenza-specific serum and lung IgG titers. Yet, only GPI-0100 also enhanced mucosal IgA titers. Moreover, only GPI-0100-adjuvanted WIV provided partial protection against heterologous virus challenge. Pulmonary immunization with GPI-0100-adjuvanted vaccine did not induce an overt inflammatory response since influx of neutrophils and production of inflammatory cytokines were moderate and transient and lung histology was normal. Our results indicate that a GPI-0100-adjuvanted dry powder influenza vaccine is a safe and effective alternative to current parenteral vaccines.
Copyright ? 2015. Published by Elsevier B.V.
KEYWORDS:
Adjuvants; Pulmonary vaccination; Spray freeze-drying; Whole inactivated virus
PMID: 25896446 [PubMed - as supplied by publisher]